This work reports the effective antitumor activity of patient-derived cytokine-induced killer (CIK) cells against autologous chemo-resistant melanoma Cancer Stem Cells (CSCs).
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells
CIK cell activity against chemoresistant mCSCs was confirmed vivo in two distinct immunodeficient murine models.
Results
We visualized eGFP + mCSCs (14±2.1%) in 11 MCs. The tumorigenic precursor rate in vivo was higher within eGFP-positive MCs (1/42) compared with the eGFP-negative counterpart (1/4870).
In vitro mCSCs were relatively resistant to CHT and BRAFi, but killed by CIK cells (n=11, 
Conclusions
These findings are the first demonstration that immunotherapy with CIK cells is active against autologous mCSCs surviving chemotherapy or BRAFi. An experimental platform for mCSC study and rationale for CIK cells in melanoma clinical study is provided.
INTRODUCTION
Malignant melanoma is the most aggressive form of skin cancer. While localized tumors are curable with surgery, treatment possibilities for metastatic melanoma have long been limited due to its minimal response to conventional anticancer treatments (1) . Recently, molecular targeted therapy and immunotherapy have greatly advanced metastatic melanoma treatment by employing respectively small molecules inhibiting mutated forms of b-raf (2-4) and immune checkpoint inhibitors ipilimumab (5), nivolumab (6, 7) , and pembrolizumab (8) to achieve such remarkable clinical trial results that they are now first-line options in international treatment guidelines (9) (10) (11) . Despite these treatments a consistent portion of patients relapse or does not achieve disease control. In addition to checkpoint inhibitors, adoptive immunotherapy also appears highly promising, and after decades of preclinical relegation, is starting to find its way into clinical applications (12, 13) . While the two approaches may be complementary, tumors containing relatively few immunogenic mutations, or those with a "non-inflamed" tumor microenvironment, continue to represent an important immunotherapy challenge. Specifically, in some non-responsive or relapsing patient subsets, or when attempting to hit tumor-sustaining targets like cancer stem cells (CSCs), adoptive infusion of ex vivo expanded antitumor immune effectors is worth consideration.
Crucial to new therapeutic strategy planning is CSC analysis and targeting because this cell subpopulation is a key factor in chemotherapeutic agent and radiation therapy resistances, contributes to post-treatment relapse, and is involved in tumor metastasis (14) (15) (16) (17) (18) (19) (20) (21) . The fact that conventional chemotherapies preferentially target actively-cycling cells, as opposed to CSCs, may implicate these observed treatment failures. Thus, exploration of novel therapeutic strategies to target CSCs with immunotherapy holds great potential (21) (22) (23) (24) (25) (26) (27) .
Among the various adoptive immunotherapy approaches we focused on an MHC-independent strategy based on cytokine-induced killer (CIK) cells (28) (29) (30) (31) (32) , which are ex vivo expanded T-NK lymphocytes with MHC-independent antitumor activity (33) (34) (35) (36) (37) (38) . The principal mechanism of tumor killing is recognition of stress-inducible tumor-restricted molecules (e.g., MIC A/B; ULBPs 1-5) by the NKG2D receptor (35, 36, 39) .
Preclinical studies of intense CIK cell activity against several tumors have been reported, as has recent evidence of their successful re-direction with chimeric-antigen receptors (CAR) (40) (41) (42) This investigation builds on our previous findings. It explores the preclinical activity of CIK cells against autologous melanoma, focusing on mCSCs that may survive conventional chemo or molecular targeted therapies. To visualize putative CSCs, we used a strategy previously validated in our lab that relies on a lentiviral vector encoding the enhanced Green Fluorescent Protein (eGFP) under expression control of the human oct4 promoter (LV.Oct4.eGFP). The underlying idea is to reveal CSCs exploiting their selective ability to activate a well-characterized stemness promoter (31, 32, 48, 49) . Our central hypothesis is that chemotherapy kills proliferating tumor cells, and thereby reduces the tumor burden, but spares CSCs that support disease relapse. We simulated this scenario in an autologous preclinical model, both in vitro and in vivo, and then assessed the efficacy of immunotherapy with CIK cells.
MATERIALS AND METHODS

Establishment of patient-derived melanoma cell cultures
Human melanoma tissues were obtained from 11 surgical specimens (lymphnodal or cutaneous metastasis); patients with advanced stage melanoma provided consent under institutional review board approved protocols. Human melanoma tissues were cut into 3-mm 3 pieces and processed for cell isolation.
Tumor tissue was processed and melanoma cells were cultured as previously described (31) .
Characterization of patient-derived melanoma cell cultures
Cell aliquots from patient-derived melanoma cell cultures were stained with FITC, PE, PE-Cyanin 7 (PC7), or APC-conjugated mouse monoclonal antibodies (mAbs) against extracellular and intracytoplasmic human antigens [anti-CD271-PE, anti-Oct4-PE, anti-Sox-2-APC, and anti-Nanog-PerCP-Cy5. 
Patient-derived Melanoma Cell Transduction
For each LV transduction, patient-derived melanoma cells were cultured in fresh KODMEM-F12 with 10%
FBS. Virus-conditioned medium was added at a dose of 400ng P24/100,000 cells. After 16h, cells were washed twice and grown for a minimum of 10 days to reach steady state eGFP expression and to rule out pseudo-transduction prior to flow-cytometry analysis (31) . As a transduction efficiency control, the same melanoma primary cells were transduced with LV.PGK.eGFP.
In vitro assessment of CSC sensitivity to fotemustine or dabrafenib
LV.Oct4.eGFP transduced melanoma cells were seeded into 6-well plates (120,000-180,000 cells/well). An early part of the experiment (group A: CIK-immunotherapy n=10, chemotherapy n=10, PBS n=8) was terminated and analyzed after 2 weeks (day+15) to assess the antitumor activity (Ki67 proliferative index) and residual rate of eGFP + mCSCs. A second branch (group B) of the experiment proceeded beyond day+15 to explore the effect of chemo-immunotherapy combination. Mice (n=12) from the initial chemotherapy cohort (treated with Fotemustine on days 1;15) started intravenous infusions with CIK cells (1x10 7 /mouse every 4-5 days from a minimum of 2 weeks to a maximum of 10 weeks); remaining mice from all the initial cohorts (CIK-immunotherapy n=12, Chemotherapy n=12, PBS n=10) worked as control and continued to be infused with PBS alone up to the end of the experiment. In all cases the experiment was terminated and animals euthanized when tumor size reached 2 cm in its main diameter, unacceptable toxicity occurred or CIK infusions ended, whoever occurred first.
Tumor growth was monitored weekly with calipers and volume calculated according to the formula: De' Pecchi -Milan, Italy) and analyzed using Summit Software.
Patient-Derived Xenografts (PDXs)
Six-week-old Non-Obese Diabetic/LtSz-scid/scid (NOD/SCID) (Charles River, Italy) female mice were subcutaneously injected with an 8 mm De' Pecchi -Milan, Italy) 3 days after transduction and analyzed using Summit Software.
Statistical analysis
Statistical analysis was performed using software GraphPad 
RESULTS
Putative melanoma cancer stem cells (mCSCs) survive chemotherapy in vitro.
Melanoma cell cultures and visualization of putative mCSCs
We established 11 melanoma cell cultures from metastatic tissue biopsied from 11 patients with advanced stage melanoma (Supplementary Table S1 ). Braf mutational analysis revealed that 5/11 of the patientderived cell cultures were braf-mutated (4 V600E: mMel3, mMel7, mMel11, mMel15, 1 V600K: mMel2).
Each culture was assessed for expression of the main melanoma surface antigens: Melanoma-associated
Chondroitin Sulfate Proteoglycan (MCSP), Nervous Growth Factor Receptor (NGFR, aka CD271), and
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) ( Table 1 Table S2) . Using this approach, the average rate of eGFP + mCSC within the 11 cultures was 12 ± 2.1% ( Table 1) . As parallel control, we confirmed that melanoma cells could be transduced efficiently (>95%) when the strong ubiquitous promoter (Phospho Glycerato Kinase, PGK, regulatory element) was utilized in place of the Oct4 promoter to control eGFP expression (Supplementary Figure S1E , S1F, Supplementary Table S2) .
Furthermore, the integration of LV.Oct4.eGFP was confirmed by PCR in both eGFP + and eGFP -melanoma cell subsets (Supplementary Figure S1G) .
Each melanoma culture was assessed for expression of the principal ligands recognized by CIK cell receptors NKG2D (MIC A/B, ULBP1, ULBP2-5-6, and ULBP3) and DNAM-1 (CD112 and CD155). As Table   1 indicates, MIC A/B and ULBP2-5-6 were expressed in all melanomas. Although sample values generally varied highly, MIC A/B and ULBP2-5-6 were comparable in eGFP + mCSC and eGFP -melanoma cells ( Figure 1A and 1B) . The expression of ULBP1, ULBP 3, CD112, and CD155 was negligible (data not shown). Also the expression of Programmed death-ligand 1 (PD-L1) was negligible (Table 1) .
Additional molecules reported in the literature as mCSC phenotype-associated were also evaluated. OCT4, NANOG, SOX2, ATP Binding Cassette G2 (ABCG2), and aldehyde dehydrogenase (ALDH) were each detected in all samples at expressions averaging 14 ± 1.3%, 12 ± 1.7%, 18± 2.1%, 6±1.3%, and 10±1.9%, respectively ( Table 2 ). Melanoma cells negative for MITF expression averaged 16 ± 4.4% (Table 2) .
Tumorigenicity of putative mCSCs
To assess the tumorigenic potential of putative eGFP + mCSCs, we subcutaneously transplanted NOD/SCID mice with scalar dilutions (from 10 to 1x10 
Sensitivity of putative mCSCs to chemotherapy or molecular targeted therapy in vitro
We explored putative mCSC sensitivity to chemotherapy treatment. Each of the 11 melanoma cell cultures was treated in vitro for 72 hours with a culture-specific dose (IC50) of fotemustine (FM) to attain a 50% melanoma kill. FM sensitivity differed among the melanomas, such that IC50 ranged between 10 and 50 ug/ml ( Figure 1D ). Activity against mCSCs was calculated by the rate of eGFP positivity among viable cells at treatment end. The rate of viable eGFP + mCSCs significantly increased after chemotherapy (mean fold increase 1.61 ± 0.04) as compared to the untreated controls (n=62 p<0.0001), which confirmed their reduced sensitivity to conventional chemotherapy ( Figure 1D ). Comparable results were obtained treating braf-mutated melanomas (n=5) with BRAFi dabrafenib (culture-specific IC50 dose, ranging between 0.08 and 5 uM). Even in this case, the reduced sensitivity of mCSCs was assumed by their increased rate (1.5 ± 0.11 fold, n=20 p<0.0001) following treatment with BRAFi dabrafenib ( Figure 1E ).
Immunotherapy with CIK cells against mCSC that survived chemo-or targeted therapy in vitro.
Generation of CIK cells from patients
CIK cell activity against the mCSCs that survived FM or BRAFi was assessed in vitro. CIK cells were generate from 8 of our 11 patients (described above), as PBMCs were unavailable for three patients in the study cohort. Within three to four weeks, cells from fresh or cryopreserved PBMCs were successfully expanded ex vivo, per a standard protocol with timed additions of IFN-gamma, Ab-anti-CD3, and IL2 (29) (30) (31) (32) Figure S2A) . Our results were comparable to previously published data (28, 29) .
Pure Natural Killer (CD3 -CD56 + ) cell presence was negligible (< 5%, data not shown). The median membrane expression of NKG2D and DNAM-1 receptors was 84% (range: 69-89%) and 97% (range: 89-100%), respectively (Supplementary Figure S2A) . 
In vitro killing of mCSCs surviving chemo-or targeted therapy by CIK cells
Immunotherapy activity of CIK cells against mCSCs in vivo
To verify that putative mCSCs can survive chemotherapy, yet retain sensitivity to immunotherapy with CIK cells, we replicated our in vitro findings in vivo. The experiments utilized NOD/SCID mice bearing tumors generated by subcutaneously-implanted LV.Oct4.eGFP-engineered melanoma cells from two different patients (mMel7 and mMel11). We explored the activity of chemotherapy and immunotherapy with CIK cells, alone and in sequence.
The experimental design is detailed in Figure 3A .
For group A, infusion of autologous CIK cells for two weeks (n=6; 1x10 7 every 4 days) and chemotherapy (n=6; 600 ug/mouse, days 1;15) yielded significant tumor (mMel11) response, indicated by significant decrease of Ki67 proliferation index (p<0.0001, Figure 3B ).
Chemotherapy spared eGFP + mCSCs that were instead killed by immunotherapy. Figure S4A and B).
In addition, we assessed the effect of sequential treatment with chemotherapy and immunotherapy (group B, Figure 3A ). In two separate experiments, CIK cells were infused intravenously (1x10 7 every 4 days) following initial treatment with FM (600µg, day 1;15). Our results indicated that CIK cells (n=12) not only retained significant antitumor activity (p<0.0001), but that they also involved putative eGFP + mCSCs. The rate of viable eGFP + mCSCs assessed in residual tumors explanted at the end of the experiments was comparable to untreated controls (n=10); on the contrary, a significant increment was observed and also maintained over time in mice treated with chemotherapy alone (n=12, p<0.05) (Figure 3D and E;
Supplementary Figure S4C and D).
The ability of CIK cells to localize and infiltrate tumor sites was confirmed by immunohistochemistry detection of CD3 + cells (Supplementary Figure 5A-C) .
Finally, CIK cell activity against putative mCSCs was confirmed in PDX models that were generated by direct subcutaneous implantation of fresh tumor samples from two patients in NOD/SCID mice (see Figure   4A and Materials and Methods). Autologous CIK cell infusion for eight weeks (1x10 7 every 7 days) exerted significant antitumor activity (n=14) as compared to untreated controls (n=13) ( Figure 4B ). The antitumor activity was shown to also involve putative mCSCs, as evidenced by no observed significant enrichment of CHT for the treatment of metastatic melanoma is less common due to the availability of more effective therapeutic approaches. Nevertheless, CHT may still be considered for patients relapsing after immunotherapy or molecular targeted treatments. In our model, the point of using FM was to functionally characterize and define the "clinical relevance" of putative mCSCs that might survive such treatment.
Furthermore, we found consistent results even in the case of BRAF-mutated melanoma treated in vitro with BRAFi. Our findings support the concept that mCSCs may be, at least partially, resistant also to molecular targeted approaches. On these bases, there may be rationale to explore synergisms with immunotherapy strategies that demonstrated activity against mCSCs.
In recent years, various CSC markers have been reported in several cancer types; however, no conclusive consensus exists. Our strategy was designed specifically to visualize a subset of melanoma cells capable of activating oct4, the main stem-related gene endowed with peculiar intrinsic biologic features. We are aware that our system may have limits and cannot ensure that all mCSCs are detected.
Nevertheless we aimed to demonstrate that the eGFP + mCSCs, even if not all of them are visualized, may survive conventional treatments but are killed by CIK cells.
Such a melanoma cell subset is less sensitive to conventional CHT compared to other melanoma cells, at least enough to be considered a relevant target from a clinical perspective.
We set up two distinct in vivo models, the first with melanoma cell cultures and the second with PDX. We observed consistent findings of chemo-and immune-sensitivity in mCSCs. When working with patientderived samples, the possibility for experimental replicates is limited. Nevertheless, the results obtained in all our models were consistent with in vitro findings. We acknowledge that our experimental design and related endpoints were conceived to assess the effect of treatments on mCSCs. Even with these considerations, mice treated with sequential chemo-immunotherapy showed a trend of improved survival compared with controls (Supplementary Figure S6) . Overall the therapeutic meaningfulness of our findings may be indirectly derived by the clinical relevance attributed to CSCs.
Our work demonstrates that immunotherapy with CIK cells is active against a "relevant" target like melanoma cells surviving chemo or molecular targeted therapy and enriched in mCSCs. Adoptive immunotherapy approaches with CIK cells could be developed and integrated with ongoing treatment strategies for selected subsets of melanoma patients.
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